Myriad Genetics (MYGN) Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.

Is FOLD or MYGN more profitable?

Myriad Genetics has a net margin of -14.09% compared to Amicus Therapeutics' net margin of -21.21%. Myriad Genetics' return on equity of -4.51% beat Amicus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amicus Therapeutics	-21.21%	-15.97%	-3.17%
Myriad Genetics	-14.09%	-4.51%	-3.07%

Which has more risk and volatility, FOLD or MYGN?

Amicus Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Do analysts rate FOLD or MYGN?

Amicus Therapeutics presently has a consensus price target of $16.88, indicating a potential upside of 74.87%. Myriad Genetics has a consensus price target of $23.92, indicating a potential upside of 87.43%. Given Myriad Genetics' higher probable upside, analysts plainly believe Myriad Genetics is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amicus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Myriad Genetics	3 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community believe in FOLD or MYGN?

Amicus Therapeutics received 60 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 73.10% of users gave Amicus Therapeutics an outperform vote while only 52.99% of users gave Myriad Genetics an outperform vote.

Company	Underperform	Outperform
Amicus Therapeutics	Outperform Votes 530 73.10%	Underperform Votes 195 26.90%
Myriad Genetics	Outperform Votes 470 52.99%	Underperform Votes 417 47.01%

Do insiders and institutionals believe in FOLD or MYGN?

99.0% of Myriad Genetics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has higher earnings and valuation, FOLD or MYGN?

Amicus Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amicus Therapeutics	$399.36M	7.22	-$151.58M	-$0.34	-28.38
Myriad Genetics	$753.20M	1.54	-$263.30M	-$1.30	-9.82

Does the media favor FOLD or MYGN?

In the previous week, Amicus Therapeutics had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 14 mentions for Amicus Therapeutics and 13 mentions for Myriad Genetics. Amicus Therapeutics' average media sentiment score of 0.79 beat Myriad Genetics' score of -0.01 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amicus Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Amicus Therapeutics beats Myriad Genetics on 10 of the 18 factors compared between the two stocks.